Growth hormone secretagogues have been a significant focus of peptide research since the identification of growth hormone-releasing hormone (GHRH) analogues in the 1980s and 1990s. Among the most studied compounds in this category are two structurally related peptides: CJC-1295 without DAC (also referred to as CJC No DAC or Modified GRF 1-29) and CJC-1295 with DAC. While both compounds share a common peptide backbone derived from the first 29 amino acids of endogenous GHRH, their pharmacokinetic profiles differ substantially due to a single chemical modification. This article is intended for researchers seeking a clearer understanding of these distinctions within a laboratory context.
Structural Background
CJC No DAC is a synthetic analogue of GHRH(1-29), engineered with four amino acid substitutions to improve stability and resistance to enzymatic degradation. Its structure was designed to more closely mimic the physiological pattern of GHRH pulsatility. CJC-1295 with DAC incorporates an additional Drug Affinity Complex (DAC) — a lysine-based side chain modification that enables covalent binding to serum albumin in the bloodstream. This binding dramatically extends the compound’s half-life from minutes to several days. Researchers can explore the broader landscape of peptide classifications in the peptide encyclopedia, which provides further structural context across compound categories.
Pharmacokinetic Differences in Research Models
The half-life distinction between the two compounds is the primary variable of interest in comparative research. CJC No DAC exhibits a plasma half-life of approximately 30 minutes, which aligns more closely with endogenous GHRH activity. CJC-1295 with DAC, by contrast, has been reported in preclinical studies to maintain detectable plasma concentrations for six to eight days following a single administration.
Research published by Jetté et al. (2005) examined the extended half-life properties of CJC-1295 with DAC in animal models, reporting sustained elevation of growth hormone and IGF-1 levels over multiple days — a profile that would not be expected from the unmodified or No DAC variant. This extended duration is directly attributable to the albumin-binding capability conferred by the DAC modification.
In contrast, CJC No DAC produces a sharper, more defined pulse of GH secretagogue activity. This pulsatile characteristic makes it of particular interest to researchers studying episodic GH release patterns and their downstream signalling effects. For those working within the growth hormone compounds category, both variants present distinct and complementary research parameters.
Key Research Differences at a Glance
- Half-life: CJC No DAC — approximately 30 minutes; CJC-1295 with DAC — approximately 6 to 8 days
- Albumin binding: Absent in No DAC; present in DAC variant via lysine modification
- GH secretion pattern: Pulsatile with No DAC; sustained and blunted with DAC
- Dosing frequency in protocols: Higher frequency observed in No DAC research models
- Research application focus: No DAC suited to acute pulsatility studies; DAC suited to chronic exposure models
Considerations for Laboratory Research Design
When designing in vitro or in vivo studies involving either compound, researchers should account for the significant differences in exposure duration and GH pulse architecture. Studies aiming to replicate physiological GH pulsatility are more likely to utilise CJC No DAC, while those investigating chronic GH axis stimulation or sustained secretagogue exposure may favour the DAC variant. Additional comparative data can be found through peer-reviewed literature; work by Alba et al. (2006) provides relevant context on growth hormone secretagogue receptor activity and downstream hormonal effects in animal models.
Researchers interested in related areas of investigation — including metabolic signalling or cellular repair pathways — may also find relevant compounds within the metabolic compounds range, where intersecting research questions frequently arise in GH axis studies.
Key Takeaways
- CJC No DAC and CJC-1295 with DAC are structurally related but pharmacokinetically distinct research compounds
- The DAC modification extends plasma half-life from approximately 30 minutes to several days via albumin binding
- CJC No DAC produces a pulsatile secretagogue profile; CJC-1295 with DAC produces a sustained one
- Research design should reflect which GH release pattern is under investigation
- Both compounds are classified as research-use-only peptides and are not approved for human use
Frequently Asked Questions
What does DAC stand for in peptide research?
DAC stands for Drug Affinity Complex. It refers to a chemical modification — specifically a reactive maleimide group on a lysine side chain — that enables a peptide to bind covalently to serum albumin in plasma, extending its half-life significantly.
Is CJC No DAC the same as Modified GRF 1-29?
Yes. CJC No DAC and Modified GRF 1-29 are frequently used interchangeably in research literature to describe the same compound — a stabilised analogue of the first 29 amino acids of GHRH without the albumin-binding DAC modification.
Which compound is more relevant for pulsatility research?
CJC No DAC is generally considered more appropriate for research into pulsatile GH release, given its shorter half-life and more defined pharmacokinetic window, which more closely resembles endogenous GHRH activity.
Where can researchers source these compounds in the UK?
UK-based researchers can review available research-grade peptides through the R&D Peptides product portfolio, which includes compounds across multiple research categories.
All compounds are for laboratory research use only. Not for human consumption. This content is intended exclusively for qualified researchers and is not directed at members of the general public.
